The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, yet its position within the broader sector now triggers questions about long-term gains. Generic versions are undercutting patent protection , leading to anxieties that investing in companies significantly dependent to Viagra's once-dominant position could be a p